Endocrine Abstracts

Aim: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity with type 2 diabetes and a few agents such as pioglitazone and metformine has been shown to beneficial effects. SGLT-2 inhibitors are used in the treatment in type 2 diabetes (T2D). It has been shown that they can the effectivenes of improve liver function in patients with NAFLD as well as in T2D. In our study we aim to elucidate the effectiveness of SGLT-2 inhibitors as second line treatment for NAFLD pati...